Navigation Links
Therapies for spinal cord injury: On the cutting edge of clinical translation
Date:8/31/2012

Charlottesville, VA (August 31, 2012). The Journal of Neurosurgery (JNS) Publishing Group is proud to announce publication of the NACTN/AOSNA Focus Issue on Spinal Cord Injury, a supplement to the September issue of the Journal of Neurosurgery: Spine, which is sponsored by AOSpine North America available in print and online. The online version of the supplement is available free to the public. The focus of this special supplement, which was spearheaded by Dr. Michael Fehlings, Professor of Neurosurgery at the University of Toronto and Medical Director of the Krembil Neuroscience Centre at the Toronto Western Hospital, is the development of cutting-edge translational research in the treatment of spinal cord injury (SCI), an often devastating injury that affects 2.5 million people worldwide, many of whom are first faced with it in early adulthood. The topic is addressed in a variety of forms in 17 articles and several editorials.

Many of the studies were conducted by members of the North American Clinical Trials Network (NACTN) for the Treatment of SCI, a consortium of 10 neurosurgery departments supplemented by a data management center and a pharmacological center. The principal investigator for the NACTN is Dr. Robert Grossman, Chairman, Department of Neurosurgery, The Methodist Hospital, Houston. Funded by the Christopher and Dana Reeve Foundation and the US Department of Defense, the NACTN was established to move molecular- and cell-based discoveries in the protection and regeneration of neuronal pathways from the laboratory to the clinical setting.

The supplement brings together papers focused on a variety of subjects related to identifying and evaluating different types of SCI, as well as developing therapeutic strategies for dealing with the disabilities that attend the injury. Graded assessments used to define the scope and extent of injury are presented and reviewed. Clinical and imaging predictors of neurological and functional outcomes, complications, and survival after SCI are identified and assessed. Original clinical studies and review articles on current and potential drug-based therapies are presented. Issues surrounding quality of life in patients with SCI are addressed. The cost-effectiveness of surgery in injured patients is examined and validated. Finally, the goals and progress of the NACTN in the transition of therapeutic strategies from preclinical to clinical settings are described.

Some interesting papers include the following:

  • "Clinical prediction model for acute inpatient complications after traumatic cervical spinal cord injury: a subanalysis from the Surgical Timing in Acute Spinal Cord Injury Study" by Jefferson Wilson and colleagues. Although most reports focus on complications occurring during the chronic stages of SCI, these authors set out to create a model to predict the development of acute complications based on clinical variables present at initial hospitalization. The authors found that that older patient age, high-energy injury mechanism, more severe neurological injury, comorbid illness, and lack of steroid medication were consistent with a greater chance of developing complications during the acute stage of SCI.
  • "Riluzole for the treatment of acute traumatic spinal cord injury: rationale for and design of the NACTN Phase I clinical trial" by Michael Fehlings et al. As the title indicates, this paper focuses on riluzole, a benzothiazole drug that conveys neuroprotection by blocking sodium channels and mitigating glutamatergic toxicity. The authors review preclinical and clinical findings on the use of riluzole, describe the Phase I trial, and suggest possible future investigations.
  • "Is surgery for cervical spondylotic myelopathy cost-effective? A cost-utility analysis based on data from the AOSpine North America prospective CSM study" by Michael Fehlings et al. In this paper the authors examine the cost-effectiveness of this surgery by looking at cost as it relates to the patient's gain in quality-adjusted life years. They found an acceptable cost-utility ratio.
  • "Translational potential of preclinical trials of neuroprotection through pharmacotherapy for spinal cord injury," by Charles Tator and others. The focus of this article is on major deficiencies in the movement of pharmacological agents with the potential for providing neuroprotection to the injured spinal cord from preclinical discovery to testing of drug safety and efficacy in the clinical setting. In a detailed study, the authors thoroughly reviewed reports of preclinical testing of glyburide, magnesium sulfate, minocycline, nimodipine, and riluzole, and recommend a strategy for creating a new scoring system that could be used to evaluate preclinical results and determine the translational readiness of neuroprotective pharmacological agents.

Spinal cord injuries arise from a two-fold assault. First, there is the initial mechanical injury to the spinal cord, which kills neural cells in the immediate vicinity of the injury and breaks neuronal pathways between the brain and other parts of the body. Second, there is a cascade of new biochemical, cellular, and vascular events that damage axons and lead to the death of previously uninjured neural cells, expanding the area of injury and leading to further neurological compromise. This special supplement to the Journal of Neurosurgery: Spine offers a unique look into current research involving the diagnosis, assessment, and treatment of patients with SCI.


'/>"/>

Contact: Gillian Shasby
gshasby@thejns.org
434-924-5555
Journal of Neurosurgery Publishing Group
Source:Eurekalert

Related biology news :

1. New discoveries about brain-hand connection sought to improve therapies, treatments, prosthetics
2. Neural stem cell transplants for spinal cord injury maximized by combined, complimentary therapies
3. By adding VSL#3 probiotic to traditional therapies UC patients can improve remission rates
4. Stem cell transplantation into mouse cochlea may impact future hearing loss therapies
5. Zebra fish point the way towards new therapies for amyotrophic lateral sclerosis
6. Aging kidneys may hold key to new high blood pressure therapies
7. Neuroprotective dietary supplements for chronic spinal cord injury
8. New studies show spinal cord injury and ALS respond to cell transplantation
9. Low oxygen levels may decrease life-saving protein in spinal muscular atrophy
10. Collaborative preclinical efficacy studies suggest a new target for drug addiction treatment
11. Ottawa researchers to lead world-first clinical trial of stem cell therapy for septic shock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2016)... 2016 Einzigartige ... und Stimmerkennung mit Passwörtern     ... MESG ), ein führender Anbieter digitaler Kommunikationsdienste, ... SpeechPro zusammenarbeitet, um erstmals dessen Biometrietechnologie einzusetzen. ... Möglichkeit angeboten, im Rahmen mobiler Apps neben ...
(Date:3/22/2016)... PROVO and SANDY, Utah ... Ontario (NSO), which operates the highest sample volume laboratory ... and Tute Genomics and UNIConnect, leaders in clinical sequencing ... announced the launch of a project to establish the ... panel. NSO has been contracted by ...
(Date:3/18/2016)... 18, 2016 --> ... ICT, Manned & Unmanned Vehicles, Physical infrastructure and Perimeter Surveillance ... in the border security market and the continuing migration crisis ... Europe has led visiongain to publish this ... --> defence & security companies in the ...
Breaking Biology News(10 mins):
(Date:4/29/2016)... , April 29, 2016 ... Transparency Market Research "Separation Systems for Commercial Biotechnology ... Trends, and Forecast 2015 - 2023", the separation ... US$ 10,665.5 Mn in 2014 and is projected ... 2015 to 2023 to reach US$ 19,227.8 Mn ...
(Date:4/28/2016)... April 28, 2016 The report ... Brayton Cryocoolers), Service (Technical Support, Product Repairs & Refurbishment, ... Global Forecast to 2022", published by MarketsandMarkets, the global ... by 2022, at a CAGR of 7.29% between 2016 ... Tables and 94 Figures spread through 159 Pages and ...
(Date:4/28/2016)... Connecticut (PRWEB) , ... April 28, 2016 , ... ... Group, Inc., will hold an open house for regional manufacturers at its Maple ... displays from Tsugami, Okuma, Hardinge Group, Chiron and Trumpf. Almost 20 leading ...
(Date:4/27/2016)... , April 27, 2016 ... (CSE: NSK) (OTCPink: NSKQB) ( Frankfurt ... an ihre Pressemitteilung vom 13. August 2015 die ... ihre Finanzen um zusätzliche 200.000.000 Einheiten auf 400.000.000 ... Dollar zu bringen. Davon wurden 157.900.000 Einheiten mit ...
Breaking Biology Technology: